Co-Authors
This is a "connection" page, showing publications co-authored by Emanuele Nicastri and Fabrizio Palmieri.
Connection Strength
1.147
-
National Institute for the Infectious Diseases "L. Spallanzani", IRCCS. Recommendations for COVID-19 clinical management. Infect Dis Rep. 2020 Feb 25; 12(1):8543.
Score: 0.217
-
Outcomes and Timing of Bedside Percutaneous Tracheostomy of COVID-19 Patients over a Year in the Intensive Care Unit. J Clin Med. 2021 Jul 28; 10(15).
Score: 0.060
-
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. J Transl Med. 2021 06 26; 19(1):272.
Score: 0.060
-
Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia. Int J Infect Dis. 2021 Jul; 108:244-251.
Score: 0.059
-
Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19. Front Pharmacol. 2021; 12:683529.
Score: 0.059
-
No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison. Front Pharmacol. 2021; 12:621676.
Score: 0.059
-
Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S82-S87.
Score: 0.058
-
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021 Apr; 105:532-539.
Score: 0.058
-
Elevated P-Selectin in Severe Covid-19: Considerations for Therapeutic Options. Mediterr J Hematol Infect Dis. 2021; 13(1):e2021016.
Score: 0.058
-
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021 04; 82(4):58-66.
Score: 0.058
-
COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. PLoS One. 2020; 15(12):e0244129.
Score: 0.058
-
Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases. Front Immunol. 2020; 11:610300.
Score: 0.057
-
Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. Int J Infect Dis. 2021 Feb; 103:607-610.
Score: 0.057
-
An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clin Infect Dis. 2020 11 19; 71(16):2272-2275.
Score: 0.057
-
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020 11 09; 222(11):1807-1815.
Score: 0.057
-
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis. 2020 10 27; 11(10):921.
Score: 0.057
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.057